PML Body Expression in Soft Tissue Sarcomas
Author Information
Author(s): Matsuo Toshihiro, Sugita Takashi, Shimose Shoji, Kubo Tadahiko, Ishikawa Masataka, Yasunaga Yuji, Ochi Mitsuo
Primary Institution: Hiroshima University
Hypothesis
The study aims to analyze the clinical significance of PML body expression in primary tumor samples from malignant fibrous histiocytoma (MFH) and liposarcoma patients.
Conclusion
The presence of PML bodies may indicate a poor prognosis for MFH and liposarcoma patients.
Supporting Evidence
- PML body immunostaining was identified in 63.9% of MFH and 63.2% of liposarcoma samples.
- Patients with PML body expression had a worse prognosis than those who did not.
- All liposarcoma patients without expression of PML were disease free at the end of the study.
Takeaway
This study found that many patients with certain types of cancer have a specific marker in their tumors that could mean they might not do well.
Methodology
Fluorescent immunostaining of PML bodies was performed in paraffin-embedded tumor sections from 55 patients.
Limitations
The study is based on a small number of samples.
Participant Demographics
The study included 55 patients, with 36 diagnosed with malignant fibrous histiocytoma and 19 with liposarcoma.
Statistical Information
P-Value
p = 0.0053 for PML body expression; p = 0.0012 for high rate of PML body expression.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website